Table 5  PAR-3 posterior extension in par-2(it5); enhancer(RNAi) one-cell and two-cell embryos (16°)
One-cell stageTwo-cell stage
RNAi% prophase–metaphase (N)a% anaphase (N)a% frequency of mislocalization in P (N)b
Control50.5 ± 5.3 (28)57.6 ± 5.0 (10)0 (41)
strd-162.8 ± 6.4* (18)58.0 ± 7.2 (8)71 (25)
pig-170.0 ± 5.8* (14)71.2 ± 6.7* (7)96 (26)
ntl-961.7 ± 8.3* (17)71.3 ± 4.9* (9)93 (46)
nop-165.4 ± 7.6* (24)68.1 ± 7.6* (8)94 (50)
math-3362.4 ± 6.0* (18)74.7 ± 6.6* (7)83 (40)
lgl-155.9 ± 2.7* (10)63.7 ± 6.9* (7)89 (35)
uba-250.2 ± 5.4 (18)57.0 ± 8.5 (3)0 (53)
Control, 25°62.8 ± 6.4* (11)89.8.0 ± 11* (2)100 (22)
  • * Value significantly different from control RNAi at 16°, P < 0.01, Student’s t test.

  • a Average size of PAR-3 domain along the anterior–posterior axis of the embryo as percentage of embryo length followed by (N), determined by immunostaining. Stage was determined by DAPI staining. Genes producing >70% embryonic lethality by RNAi in par -2(it5) at 16° were used for this analysis.

  • b Percentage of embryos exhibiting abnormal PAR-3 extension in the posterior P1 cell.